| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Cytochrome P450 2C8 |
|---|
| Ligand | BDBM50271463 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_552426 (CHEMBL1001843) |
|---|
| IC50 | >100000±n/a nM |
|---|
| Citation |  Raghavan, S; Tria, GS; Shen, HC; Ding, FX; Taggart, AK; Ren, N; Wilsie, LC; Krsmanovic, ML; Holt, TG; Wolff, MS; Waters, MG; Hammond, ML; Tata, JR; Colletti, SL Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists. Bioorg Med Chem Lett18:3163-7 (2008) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Cytochrome P450 2C8 |
|---|
| Name: | Cytochrome P450 2C8 |
|---|
| Synonyms: | CP2C8_HUMAN | CYP2C8 | CYPIIC8 | Cytochrome P450 2C8 (CYP2C8) | P450 IIC2 | P450 MP-12/MP-20 | P450 form 1 | S-mephenytoin 4-hydroxylase |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 55839.23 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P10632 |
|---|
| Residue: | 490 |
|---|
| Sequence: | MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV
|
|
|
|---|
| BDBM50271463 |
|---|
| n/a |
|---|
| Name | BDBM50271463 |
|---|
| Synonyms: | (R)-2-(3-(1-(4-hydroxyphenyl)-5-methyl-1H-pyrazol-4-yl)-2-methylpropanamido)cyclohex-1-enecarboxylic acid | CHEMBL483934 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C21H25N3O4 |
|---|
| Mol. Mass. | 383.4409 |
|---|
| SMILES | C[C@H](Cc1cnn(c1C)-c1ccc(O)cc1)C(=O)NC1=C(CCCC1)C(O)=O |r,t:21| |
|---|
| Structure | 
|
|---|
Search and Browse
